CRSP stock: buy or sell
Updated on:
Jan 27th, 2021
2
CRSP stock brief
- CRISPR Therapeutics closed on Tuesday at $169.53 after collapsing a -6.46%.
- Price is drawing a scaled uptrend since September 2020 with higher tops and higher bottoms. Up to date, shares marked a 121.00% gain since the beginning of this rally
- CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases.
Should I buy CRISPR Therapeutics stock?
Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best
Is $CRSP stock a buy?
In the current situation of CRISPR Therapeutics there is not any eligible buy setup. This doesn't mean we expect a selloff for $CRSP in the next few days, or that it may not rise higher. Simply, it doesn't match our recommended trading systems
Should I sell CRISPR Therapeutics stock?
Do you know when is it time to sell CRISPR Therapeutics?. Trading strategies help us to avoid impetuous decisions based on our personal emotions or the noise that surrounds the market. We like very simple setups to guide us on when is a good time to sell a stock. Be aware that these setups should not be used for shorting $CRSP stock
As a golden rule, you should not keep a trading operation that shows a losses greater than those expected by the time of purchase. The timing to sell your stock should always be determined by the stop-loss (automatic or manual)
Is it time to sell CRISPR Therapeutics stock?
Currently, CRISPR Therapeutics stock doesn't match any of our preferred sell setups, so if you own CRISPR Therapeutics shares and your operation is in profit probably is not time to sell now
CRISPR Therapeutics ratings
In the last 30 days, just one analyst rating was published for CRISPR Therapeutics
| Brokerage firm | Rating |
|---|---|
| Jan 12th, 2021 | |
| Truist | Neutral |
CRISPR Therapeutics stock analysis
CRISPR Therapeutics stock started an uptrend in September 2020, and gained a gorgeous 121.00%. The price line shows higher peaks and higher lows, and along the way provided some buy points for those who wanted to enter. Latest low was last November, when price bounced at $84.38. Now, the price moves in a consolidation between its last top ($220.20) and its last bottom ($84.38)
SMAs overview
Supports and resistances
The current resistances are:
The current support levels are:
Bollinger bands
Since the price surpassed the upper band on January 14, the price sliced by 21.19%
Relative strength index
The RSI dropped below the overbought level of 70 on January 15 after just crossing to the overbough zone for 1 day (weak signal). The RSI value on Tuesday was 47.24. CRISPR Therapeutics shares sank a 19.29% since that level was lost
CRISPR Therapeutics stock price history
CRISPR Therapeutics started trading on Oct 19th, 2016 at $15.00 per share1. Since then, CRSP stock surged by 1,030.20%, with an average of 257.55% per year. An investment of thousand dollars on Oct 2016 would worth $11,302.00 nowadays.
1: Adjusted price after possible price splits or reverse-splits
Price target for CRISPR Therapeutics stock
Nobody can predict how much a share will be priced in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts.
The following table shows the price predictions published by analysts in the last month. Again, these predictions are not direct recommendations for individual traders and must not be followed blindly.
There is just one price target available for CRISPR Therapeutics that forecasts a price of $210.00.
| Brokerage firm | Price target |
|---|---|
| Jan 12th, 2021 | |
| Truist | $170.00 → $210.00 |
Earnings and financials
CRISPR Therapeutics ($CRSP) had the quarterly financial call and presented the report last October. The company posted adjusted EPS that lowered analysts' expectations. Quarterly EPS was $-1.32 per share vs the estimates of $-1.18.
Same quarter one year ago, reported EPS was $2.40, so recently reported EPS means a reduction of -155.00%. Sales sank a -99.93% on an annualized basis in the , from $2.1B to $1.5M last quarter.CRSP ($CRSP) presents Q4 earnings report next Wednesday. Wall Street analysts predict of $-1.27, that is a 3.79% higher than Q3.
CRISPR Therapeutics competitors
CRISPR Therapeutics belongs to the Biotechnology industry and the Healthcare sector. In the last 3 months, CRISPR Therapeutics performed a 86.20% and its main competitor, Pieris Pharmaceuticals, performed a 22.80%.
CRISPR Therapeutics performance
To better understand CRISPR Therapeutics performance you must compare its gains with other related stocks in same sector or industry.. For CRISPR Therapeutics, the benchmark is made against Pieris Pharmaceuticals.
| Company | 1m | 3m | 6m |
|---|---|---|---|
| CRISPR Therapeutics ($CRSP) | -4.50% | 86.20% | 85.80% |
| Pieris Pharmaceuticals (PIRS) | -0.40% | 22.80% | -1.10% |
Important note:
The comments written in this post are personal and should not be followed as recommendations for you to buy or sell shares. The author of this report does not have an understanding of the specific scenarios of the reader, his or her own financial statements or his or her own best interests at any given time. All users should speak with their financial advisor before buying or selling any securities Opinions are expressed for educative reasons onlyCRSP summary
| Tuesday, January 26th, 2021 | |
|---|---|
| Open | $179.09 |
| Close | $169.53 |
| Day range | $168.51 - $183 |
| Previous close | $181.24 |
| Session gain | -6.46% |
| Average true range | $19.17 |
| 50d mov avg | $152.67 |
| 100d mov avg | $121.78 |
| 200d mov avg | $97.64 |
| Earnings date | February 10th, 2021 |